Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial

[1]  J. Cuzick,et al.  CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. , 2012, Journal of the National Cancer Institute.

[2]  P. Neven,et al.  CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. , 2012, Journal of the National Cancer Institute.

[3]  Stephen W Duffy,et al.  A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.

[4]  S. Suissa,et al.  Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence , 2011, Breast Cancer Research and Treatment.

[5]  Vered Stearns,et al.  CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance , 2010, Current oncology reports.

[6]  H. Brauch,et al.  Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach? , 2009, European journal of cancer.

[7]  Lang Li,et al.  Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort , 2009, Breast Cancer Research and Treatment.

[8]  J. Cuzick,et al.  Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. , 2008, The Lancet. Oncology.

[9]  Lei He,et al.  Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Yusuke Nakamura,et al.  Impact of CYP2D6*10 on recurrence‐free survival in breast cancer patients receiving adjuvant tamoxifen therapy , 2008, Cancer science.

[11]  L. Natarajan,et al.  Tamoxifen, hot flashes and recurrence in breast cancer , 2008, Breast Cancer Research and Treatment.

[12]  Wolfgang Simon,et al.  Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Hyeong-Seok Lim,et al.  Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  B. Bonanni,et al.  Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. , 2007, Journal of the National Cancer Institute.

[15]  J. Cuzick,et al.  Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. , 2007, Journal of the National Cancer Institute.

[16]  J. Cuzick,et al.  Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  B. Bonanni,et al.  Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Zeruesenay Desta,et al.  Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment , 2006, Clinical pharmacology and therapeutics.

[19]  David A. Flockhart,et al.  The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen , 2006, Breast Cancer Research and Treatment.

[20]  Fergus J Couch,et al.  Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Scheys,et al.  Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients , 2005, Breast Cancer Research and Treatment.

[22]  L. Skoog,et al.  Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients , 2005, Breast Cancer Research.

[23]  David A. Flockhart,et al.  Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[24]  P. Boyle,et al.  Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. , 2003, Journal of the National Cancer Institute.

[25]  M Baum,et al.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.

[26]  C. Baker,et al.  Breast cancer treatment. , 1999, Nurse practitioner forum.